Publications by authors named "I E Penner"
Given the association of Epstein-Barr virus (EBV) with subjective perception of fatigue and demyelination in clinical conditions, the question about potential subclinical effects in the adult general population remains open. We investigate the association between individuals' EBV immune response and perceived fatigue in a community dwelling cohort (n = 864, age 62 ± 10 years old; 49% women) while monitoring brain tissue properties. Fatigue levels are assessed with the established fatigue severity scale, the EBNA-1 and VCA p18 immunoglobulin G (IgG) chronic response - with multiplex serology and the estimates of local brain volume, myelin content, and axonal density - using relaxometry- and multi-shell diffusion-based magnetic resonance imaging (MRI).
View Article and Find Full Text PDFBackground: Best supportive care (BSC) measures are an essential component for the management of primary progressive multiple sclerosis (PPMS).
Objectives: RETRO PPMS (ML39631) is the first study to systematically analyze the therapeutic journey and standard of BSC of patients with PPMS in Germany.
Design: This multicenter, non-interventional study retrospectively analyzed patient charts.
Article Synopsis
- Cognitive impairment is a significant issue in myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD), with a study showing that about 21.9% of patients experience cognitive deficits, particularly in mental flexibility and attention.
- The study involved 32 MOGAD patients and analyzed clinical factors like age and previous relapses, finding that the overall number of relapses and past episodes of acute disseminated encephalomyelitis (ADEM) were linked to increased cognitive impairment risk.
- MRI results indicated that patients with MOGAD had reduced white and deep gray matter volumes compared to healthy controls, highlighting potential neurological damage in this condition.
Article Synopsis
- Cladribine tablets are used to treat relapsing multiple sclerosis (RMS) with a treatment regimen of two annual courses, totaling 20 days, and the study focuses on patient experiences right after its launch.
- A multicenter study in Germany evaluated the effectiveness, tolerability, and patient satisfaction over a 24-week period, involving 491 RMS patients with an average satisfaction score of 75.6 at week 24.
- Most patients reported high treatment satisfaction and an increase in overall satisfaction after switching from other medications, with a majority remaining relapse-free and only a small percentage experiencing adverse events.